ReviewJAC-antimicrobial resistance2025
Tetracycline-resistant
Review in JAC-antimicrobial resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- Comparing Phenotypic Susceptibility Profiles of Neisseria gonorrhoeae for Tetracycline and Doxycycline.Sexually transmitted diseases · 2026Article
- Tetracycline Resistance Among Neisseria gonorrhoeae Isolates-United States, 1987-2022.Sexually transmitted diseases · 2026Article
- Awareness, Usage and Perceptions of Doxycycline Post-Exposure Prophylaxis (doxyPEP) for Prevention of Sexually Transmitted Infections in Australia: Insights From a National Cross-Sectional Survey.The Medical journal of Australia · 2026Article
- High prevalence of tetracycline resistance inEuro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2026Article
- Southern African HIV Clinicians Society guideline on doxycycline post-exposure prophylaxis to prevent bacterial sexually transmitted infections.Southern African journal of HIV medicine · 2026Article
- A Review of Doxycycline Post-Exposure Prophylaxis and Its Implications for Antimicrobial Resistance and the Human Microbiome.Infectious diseases and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: Doxycycline post-exposure prophylaxis (doxyPEP) can reduce incident sexually transmitted infections including gonorrhoea for MSM and transgender women. Its effectiveness depends on the level of tetracycline resistance in Methods: We searched bibliographic databases (1 January 2000 to 26 August 2024) for English-language studies reporting tetracycline MIC with a sample size of >10 isolates. Data on country, year, sex, sexual orientation and infection site were collected. Countries were grouped into seven World Bank regions. Tetracycline resistance (MIC > 1 mg/L) was reported by country, region and time period (2010-23 versus 1996-2009). Results: Sixty-seven included studies from 51 countries studying 80 645 isolates (91% from 2010-23) were analysed. Overall median tetracycline resistance was 54.2% (range 4.0%-100.0%). Highest resistance occurred in East Asia and Pacific (82.1%, 18%-100%) and sub-Saharan Africa (81.6%, 44%-100%), and lowest in North America (26.5%, 4%-78%). Only 16% (11/67) of studies reported MSM, 18% (12/67) included oropharyngeal isolates and 9% (6/67) included women. Resistance increased by 3-4-fold in South Asia [relative risk (RR) 3.8] and North America (RR 4.1) over time. Conclusions: High and rising tetracycline resistance limits doxyPEP's potential to prevent gonorrhoea. More data are needed from MSM, women and oropharyngeal sites to understand AMR trends and transmission dynamics between MSM and women.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.